Prolastin

Prolastin

a trademark for alpha1-antitrypsin (alpha1-proteinase inhibitor, human).
References in periodicals archive ?
5, 2013 /PRNewswire/ -- Grifols, a global healthcare company based in Barcelona, Spain, is commemorating the 25th anniversary year of PROLASTIN (alpha1-proteinase inhibitor[human]) and the 50th anniversary of the discovery of alpha1-antitrypsin deficiency (Alpha1) with a series of events and programs around the world aimed at raising awareness and advancing research into the treatment of alpha1.
Prolastin is not indicated for use in patients other than those with the a specific genetic phenotype.
Talecris developed and manufactures Prolastin (Alpha1-Proteinase Inhibitor [Human]), a leading treatment for alpha1-antitrypsin deficiency.
Scientists at Cardiff-based BBI will work with the Talecris researchers to develop a tool which will identify patients who may benefit from treatment with the US company's Prolastin therapy.
For many years, the only commercially available augmentation therapy was Prolastin (Bayer), a human alph[a.
Current treatment for AAT deficiency often involves augmentation of the AAT protein itself via intravenous infusion of Prolastin, which is purified AAT derived from pooled human plasma (Sandhaus 1993, 2001; Stoller et al.
Lioresal baclofen Treatment of intractable Intrathecal spasticity caused by spinal cord injury, multiple sclerosis, other spinal diseases Lupron injection leuprolide acetate Treatment of central Prolastin alpha-1 -proteinase precocious puberty inhibitor (human) Replacement therapy in the alpha-1 -proteinase inhibitor congenital deficiency state Survanta beractant Prevention and treatment of intratracheal neonatal respiratory suspension distress syndrome.
As the manufacturer of PROLASTIN (Alpha (1)-Proteinase Inhibitor[Human]) and Trypsone, treatments for AAT deficiency, Grifols demonstrates its ongoing commitment to the alpha (1) community through eALTA and other research programs.
Stern, commented: "We are pleased to see continued growth in end user demand for both Gamunex, our brand of IGIV, as well as PROLASTIN, our brand of alpha-1 proteinase inhibitor for the treatment of genetic emphysema, as compared to the first quarter of 2009[.
We were pleased to see higher revenues for Gamunex, our brand of IGIV, as well as Prolastin, our brand of alpha-1 proteinase inhibitor for the treatment of genetic emphysema, as compared to the 2008 fourth quarter," said Lawrence D.